REGENXBIO CFO Chan Mitchell forfeited 4,902 shares at $9.32 per share on September 1, 2026. His ownership afterward stood at 122,815 shares. The transaction gives investors a specific post-transaction holding for the company’s chief financial officer, while the reported price and share count define the forfeiture.
Key Highlights
- The transaction occurred on September 1, 2026.
- Chan Mitchell serves as REGENXBIO’s chief financial officer.
- Mitchell owned 122,815 REGENXBIO shares after the transaction.
REGENXBIO Inc. (NASDAQ: RGNX) Chief Financial Officer Chan Mitchell forfeited 4,902 shares at $9.32 per share on September 1, 2026. The transaction left Mitchell owning 122,815 shares of REGENXBIO Inc.
4,902 Shares Forfeited at $9.32
The transaction involved 4,902 REGENXBIO shares, with the stated value set at $9.32 per share. Mitchell was identified as the company’s chief financial officer. The recorded transaction date was September 1, 2026. His ownership following the transaction was 122,815 shares.
Post-Transaction Ownership
Mitchell’s reported holding after the forfeiture was 122,815 shares. The reported transaction price was $9.32 per share, while the forfeited amount was 4,902 shares.
FAQs
Q: How many REGENXBIO shares did Chan Mitchell forfeit?
A: REGENXBIO CFO Chan Mitchell forfeited 4,902 shares. The shares were valued at $9.32 per share in the reported transaction. The filing identifies him as the company’s chief financial officer.
Q: How many REGENXBIO shares did Mitchell own afterward?
A: The filing reports that Chan Mitchell owned 122,815 REGENXBIO shares following the transaction. It identifies Mitchell as the company’s chief financial officer in that filing.
Q: When did the REGENXBIO share forfeiture occur?
A: The REGENXBIO share forfeiture occurred on September 1, 2026, according to the filing. The transaction covered 4,902 shares at $9.32 per share.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.